Neumentum has entered into a global licensing agreement with J&J's Janssen Pharmaceuticals for the rights to novel oral analgesic candidate, JNJ-10450232.
JNJ-10450232, which is neither an opioid nor an NSAID, is targeted for moderate to moderately severe acute pain. Phase 2A clinical studies were completed for the compound in 2015, but progress has stalled since the study completion.
Neumentum is a California-based specialty pharma company that focuses on non-opioid analgesic and neurology. The drugmaker says the deal will significantly expand its pipeline of investigational pain therapies aimed at addressing the growing need for innovative analgesics.
Read the press release